文献速递MDS 与骨髓增殖性肿瘤

原发性血小板增多症纤维化进展的临床与分子预测因素:涉及1607例患者的多中心研究

Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients.
PubMed 文献 · Am J Hematol · 2021-09-06

该回顾性多中心研究纳入1607例WHO定义的原发性血小板增多症(ET)患者,在佛罗伦萨队列中识别无骨髓纤维化生存(MFS)的独立危险因素,并建立分子风险分层,后在梅奥诊所和罗马队列中验证。高分子风险组(JAK2V617F VAF>35%、CALR 1/1-like或MPL突变)较低于低分子风险组的纤维化转化风险显著更高。

要点

  • 年龄>60岁、男性、可触及脾肿大、CALR 1/1-like或MPL突变、JAK2V617F VAF>35%为MFS独立危险因素。
  • 高分子风险定义为JAK2V617F VAF>35%、CALR 1/1-like或MPL突变,其余驱动突变归为低分子风险。
  • 高分子风险组纤维化转化风险显著高于低分子风险组,各队列风险比分别为6.1、2.5、2.7。

核心结论

  • 研究提供了ET纤维化转化的实用风险信号,有助于识别需要密切监测和适当咨询的患者。

研究设计与样本

  • 回顾性多中心研究,纳入1607例WHO定义的ET患者,来自佛罗伦萨(n=718)、梅奥诊所(n=479)和罗马(n=410)三个独立队列。
  • 先在佛罗伦萨队列中识别MFS独立危险因素,再建立分子风险分层并在梅奥和罗马队列中验证。

主要发现

  • 佛罗伦萨队列中MFS独立危险因素包括年龄>60岁(HR 2.5,95%CI 1.3-4.9)、男性(HR 2.1,95%CI 1.2-3.9)、可触及脾肿大(HR 2.1,95%CI 1.2-3.9)、CALR 1/1-like或MPL突变(HR 3.4,95%CI 1.9-6.1)、JAK2V617F VAF>35%(HR 4.2,95%CI 1.6-10.8)。
  • 高分子风险组vs低分子风险组纤维化转化风险:佛罗伦萨队列10年8% vs 1.2%,20年33% vs 8%(p<0.001;HR 6.1,95%CI 3.2-11.7)。
  • 梅奥队列10年16% vs 7%,20年44% vs 25%(p<0.001;HR 2.5,95%CI 1.6-4.1)。
  • 罗马队列10年7.8% vs 4.6%,20年31.2% vs 7.1%(p=0.007;HR 2.7,95%CI 1.3-5.8)。

关键数值与推荐

  • 高分子风险类别:JAK2V617F VAF>35%、CALR 1/1-like或MPL突变;其余驱动突变谱归为低分子风险类别。

临床怎么用

  • 可根据年龄、性别、脾肿大及分子风险分层(JAK2V617F VAF>35%、CALR 1/1-like或MPL突变)识别纤维化转化高风险ET患者。
  • 对高分子风险患者应考虑密切监测和适当咨询。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The current retrospective study involving a total of 1607 patients was designed to identify clinical and molecular variables that were predictive of inferior myelofibrosis-free survival (MFS) in WHO-defined essential thrombocythemia (ET), utilizing three independent patient cohorts: University of Florence, Italy (n = 718); Mayo Clinic, USA (n = 479) and Policlinico Gemelli, Catholic University, Rome, Italy (n = 410). The Florence patient cohort was first examined to identify independent risk factors for MFS, which included age > 60 years (HR 2.5, 95% CI 1.3-4.9), male sex (2.1, 1.2-3.9), palpable splenomegaly (2.1, 1.2-3.9), CALR 1/1-like or MPL mutation (3.4, 1.9-6.1) and JAK2V617F variant allele frequency > 35% (4.2, 1.6-10.8). Subsequently, an operational molecular risk category was developed and validated in the other two cohorts from Mayo Clinic and Rome: "high molecular risk" category included patients with JAK2V617F VAF >35%, CALR type 1/1-like or MPL mutations; all other driver mutation profiles were assigned to "low molecular risk" category. The former, compared to the latter molecular risk category, displayed significantly higher risk of fibrotic transformation: Florence cohort with respective fibrotic transformation risk rates of 8% vs. 1.2% at 10 years and 33% vs. 8% at 20 years (p < 0.001; HR 6.1; 95% CI 3.2-11.7); Mayo Cohort, 16% vs. 7% at 10 years and 44% vs. 25% at 20 years (p < 0.001; HR 2.5; 95% CI 1.6-4.1); and Rome cohort 7.8% vs. 4.6% at 10 years and 31.2% vs. 7.1% at 20 years (p = 0.007, HR 2.7; 95% CI 1.3-5.8). The present study provides practically useful risk signals for fibrotic transformation in ET and facilitates identification of patients who require close monitoring and appropriate counseling.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Loscocco GG, Guglielmelli P, Gangat N, et al. Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients. Am J Hematol. 2021. PMID: 34424575. doi:10.1002/ajh.26332

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。